Pharmaceutical Technology E-Alert:
Having trouble viewing this e-mail? Click here. 		You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile.
BLOG
EVENT CALENDAR
COLUMNS
WHITE PAPERS
THE MAGAZINE
  Pharmaceutical Technology Europe E-Alert
 
2 July 2010
IN THIS ISSUE
• PTE Digital July issue
 • Anti-counterfeit strategy
• Top technologies
 • Novartis/Alcon merger
The present and the future of anti-counterfeit technologies
Counterfeit pharmaceuticals are an ever-growing problem, but changing regulations in Europe are forcing companies to take note and adopt an anti-counterfeit solution. PTE examines the incoming anti-counterfeiting legislation and some of the new technologies — from Data Matrix to edible microtags — that can help protect supply chains. More...		  
 
Obstacles to implementing an effective anti-counterfeit strategy: can they be overcome?
Can the effects of counterfeiting ever be truly measured? Will a global track and trace solution ever be put in place? And is the pharma industry ready to fight the counterfeiters? The Managing Partner at Pharma Pieces answers these questions and more. More...		  
 
Anti-counterfeit equipment product showcase
A range of some of the top anti-counterfeit technologies available on the European market. More...		  
 
Novartis cannot force Alcon merger
The merger Novartis has been trying to unilaterally impose on Alcon cannot go ahead without the approval of Alcon’s Independent Director Committee (IDC), according to a legal expert, and at the moment the IDC still believes that Novartis’s offer is vastly inadequate. More...
 
FDA issues draft guidance on CMC post-approval changes
The FDA has issued draft guidance for industry that provides recommendations to drug applicants about the types of changes that may be included in annual reports. More...
 
Improvements to FDA’s regulation of foreign clinical trials recommended
The Office of the Inspector General for the Department of Health and Human Services (HHS) issued a report, which provides recommendations to FDA on how to improve its oversight of foreign clinical trials. More...
 
Join our community on LinkedIn
Want to discuss any of this week’s news stories or any other hot topics in the industry? Then why not join our group on LinkedIn? More...
 
Event Profile
Smithers
TheExtractables & Leachables for Pharmaceutical Products 2010
Date: 14-15 September 2010
Venue: Holiday Inn London Kings Cross Bloomsbury, London

Impurities originating from any part of the manufacturing or storage of drug products can potentially result in expensive product recalls and damage to a company’s reputation, not to mention the serious threat posed to patient safety.

Read more...
 
Podcast
Vetter
The North American market is critical to Vetter’s strategic global growth as nearly half of its client base is already located here. In order to maximize on this opportunity, Vetter has decided to create a facility, its first outside of Germany, at the Illinois Science + Technology Park in suburban Chicago.

Read more...


Survey
Should the FDA have mandatory recall authority and the power to halt drug production?
■   Yes 72%
■   No 28%

This week we would like to know...

If your company was considering/is developing a biosimilar product, what would be your biggest concern?
Click here to vote

Contact Us
Click here to contact editorial.

Click here to contact sales.

 
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact
information available to third parties for marketing purposes, please contact us by emailing magazines@superfill.com or by mail at Advanstar Communications Inc., Advanstar House, Park West, Sealand Road, Chester, CH1 4RN United Kingdom